[12] Loibl S, Mano M, Untch M, et al. Phase III study of adjuvant ado-trastuzumab emtansine vs trastuzumab for residual invasive HER2-positive early breast cancer after neoadjuvant chemotherapy and HER2-targeted therapy: K...
[4]https://www.astrazeneca-us.com/media/press-releases/2024/enhertu-approved-in-the-us-as-first-tumor-agnostic-her2-directed-therapy-for-previously-treated-patients-with-metastatic-her2-positive-solid-tumors.html [5]h...
in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol 2018;36:
首先还是一样，展示一下最新版NCCN指南上，对于HER-2靶向二线药是怎么推荐的？SYSTEMIC THERAPY REGIMENS FOR RECURRENT OR STAGE IV(M1) DISEASE，这就是说如果是复发RECURRENT或者是四级的癌症，就是已经M1，M1的意思就是已经远端转移了，这样的癌症，怎么去用药。首先它是HER2-Positive，就是HER-2还是阳性的，就...
[18] Xu B, Ma F, Ouyang Q, et al. Abstract PD3-08: A randomized phase II trial of pyrotinib plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with taxanes, anthracyclines and/or trastuzumab[J]. 2018. ...
[5] Baez-Vallecillo L, Raghavendra AS, Hess KR, et al. Lapatinib activity in metastatic human epidermal growth factor receptor 2-positive breast cancers that received prior therapy with trastuzumab, pertuzumab, and/or ado-trastuzumab emtansine (T-DM1). Breast Cancer Res Treat 2019;176(1):227...
近日,山东大学材料学院蒋妍彦团队在Advanced Science(IF=16.8 一区)杂志上发表了题为:“A Multifunctional Bimetallic Nanoplatform for Synergic Local Hyperthermia and Chemotherapy TargetingHER2-Positive Breast Cancer.”的文章,研究团队开发了一个纳米治疗平台,结合了双金属金银空心纳米壳、吡咯替尼和赫赛汀,实现了多...
1. Gion M, Trapani D, Cortés A, et al. Systemic Therapy for HER2-Positive Metastatic Breast Cancer: Moving Into a New Era. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-11. 2. Romond EH, et al. Seven year follow-up assessment of cardiac functionin NSABPB-31. a randomized trial co...
[1]Nader-Marta G,Martins-Branco D,de Azambuja E.How we treat patients with metastatic HER2-positive breast cancer.ESMO Open.2022 Feb;7(1):100343. [2]Prat A,Guarneri V,ParéL,et al.A multivariable prognostic score to guide systemic therapy in early-stage HER2-positive breast cancer:a retr...
HER2阳性mCRC的靶向治疗研究不仅稀少，而且现有的治疗方案评估往往缺乏综合性和系统性的分析。对此，《Current Oncology》杂志于2023年9月发表的一项Meta分析研究《A Meta-Analysis to Assess the Efficacy of HER2-Targeted Treatment Regimens in HER2-Positive Metastatic Colorectal Cancer (mCRC)》（《一项评估HER2靶向...